Franny Jongbloed

64 CHAPTER 3 Table 2. Overview of the top overrepresented canonical pathways in tumor ranked by their P- value Canonical Pathway Pathway classification P- value Genes Ratio Z-score Tumor – AL vehicle vs. AL irinotecan PTEN Signaling Apoptosis; Cancer 1.57 E -02 7/119 (5.9%) +2.646 P53 Signaling Cancer 3.51 E -02 6/111 (5.4%) +1.342 Apoptotic Signaling Apoptosis 4.74 E -02 5/90 (5.6%) +1.000 Glioma Signaling Cancer 7.94 E -04 9/112 (8.0%) -2.121 Neuropathic Pain Signaling in Dorsal Horn Neurons Neurotransmitters and Other Nervous System Signaling 3.78 E -05 8/115 (7.0%) -2.121 CREB Signaling in Neurons Neurotransmitters and Other Nervous System Signaling; Cellular Growth, Proliferation and Development 2.08 E -02 9/185 (4.9%) -2.121 Nitric Oxide Signaling in the Cardiovascular System Cardiovascular Signaling 3.78 E -02 6/113 (5.3%) -2.000 Huntington’s Disease Signaling Neurotransmitters and Other Nervous System Signaling 4.18 E -02 10/243 (4.1%) -1.890 Synaptic Long Term Potentiation Neurotransmitters and Other Nervous System Signaling 4.99 E -02 6/121 (5.0%) -1.633 STAT3 Pathway Cellular Growth, Proliferation and Development; Transcriptional Regulation 2.30 E -02 5/74 (6.8%) -1.342 Synaptic Long Term Depression Neurotransmitters and Other Nervous System Signaling 4.29 E -02 7/147 (4.8%) -1.134 Tumor – Fasting vehicle vs. Fasting irinotecan Signaling by Rho Family GTPases Intracellular and Second Messenger Signaling 1.10 E -03 35/248 (14.1%) +3.286 Gaq Signaling Intracellular and Second Messenger Signaling 2.26 E -02 21/161 (13.0%) +2.828 IL-9 Signaling Apoptosis; Cytokine Signaling; Cellular Immune Response 2.81 E -02 8/45 (17.8%) +2.828 CD40 Signaling Humoral Immune Response; Cellular Immune Response 1.85 E -04 17/79 (21.5%) +2.668 TNFR2 Signaling Apoptosis; Cytokine Signaling 9.29 E -03 7/30 (23.3%) +2.646 Type II Diabetes Mellitus Signaling Cellular Stress and Injury 8.16 E -03 19/128 (14.8%) +2.500 Colorectal Cancer Metastasis Signaling Cancer 1.31 E -04 38/248 (15.3%) +2.401 ILK Signaling Cellular Growth, Proliferation and Development 6.47 E -04 30/196 (15.3%) +2.353 Wnt/Ca+ pathway Cancer; Organismal Growth and Development 1.84 E -02 10/58 (172%) +2.333 RANK Signaling in Osteoclasts Cellular Growth, Proliferation and Development 6.79 E -05 21/102 (20.6%) +2.236 Aryl Hydrocarbon Receptor Signaling Cell Cycle Regulation; Apoptosis; Xenobiotic Metabolism; Nuclear Receptor Signaling 8.10 E -06 28/140 (20.0%) +2.200 Acute Myeloid Leukemia Signaling Cancer 4.85 E -04 18/93 (19.4%) +2.183 Huntington’s Disease Signaling Neurotransmitters and Other Nervous System Signaling 4.74 E -07 44/243 (18.1%) +2.132